Product ID | 35573-430_24b2c766-501b-4d7f-99aa-1fd8a8ee3ea4 |
NDC | 35573-430 |
Product Type | Human Prescription Drug |
Proprietary Name | Abacavir and Lamivudine |
Generic Name | Abacavir And Lamivudine |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2019-11-15 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA090159 |
Labeler Name | Burel Pharmaceuticals, Inc. |
Substance Name | ABACAVIR SULFATE; LAMIVUDINE |
Active Ingredient Strength | 600 mg/1; mg/1 |
Pharm Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |